DOCSLIB.ORG

Clemizole Hydrochloride/Deptropine Citrate

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clemizole Hydrochloride/Deptropine Citrate Clemizole Hydrochloride/Deptropine Citrate 575 unsuitable for the prolonged treatment that may be re- UK licensed product information states that cyproheptadine may embolisation, a procedure sometimes used to relieve the symp- quired in palliative care. See also under Interactions, cause a false positive test result for tricyclic antidepressants in toms of carcinoid syndrome.2 There have been a few reports of urine. tumour regression, in addition to symptomatic control, after above. 3,4 1. Bivens CH, et al. Inhibition of hypoglycaemia-induced growth treatment of carcinoid tumours with cyproheptadine. Preparations hormone secretion by the serotonin antagonists cyproheptadine 1. Caplin ME, et al. Carcinoid tumour. Lancet 1998; 352: 799–805. and methysergide. N Engl J Med 1973; 289: 236–9. 2. Maton PN, et al. Role of hepatic arterial embolisation in the car- BP 2008: Cyclizine Injection; Cyclizine Tablets; Dipipanone and Cyclizine cinoid syndrome. BMJ 1983; 287: 932–5. Correction to dosage. Ta bl e t s ; Interactions ibid.; 1664. USP 31: Cyclizine Hydrochloride Tablets. 3. Harris AL, Smith IE. Regression of carcinoid tumour with cy- As for the sedating antihistamines in general, p.563. Proprietary Preparations (details are given in Part 3) proheptadine. BMJ 1982; 285: 475. 4. Leitner SP, et al. Partial remission of carcinoid tumor in response Austria: Echnatol; Denm.: Marzine; Fin.: Marzine; Hong Kong: Marzine†; Antidepressants. For reports suggesting that cyproheptadine to cyproheptadine. Ann Intern Med 1989; 111: 760–1. Valoid†; India: Medazine; Irl.: Valoid; Neth.: Kruidvat Reistabletten; can reduce the effectiveness of SSRIs, see under Fluoxetine, Norw.: Marzine; NZ: Marzine; Nausicalm; Valoid; S.Afr.: Aculoid; Cov- p.396. Serotonin syndrome. Cyproheptadine has been successfully amet; Emitex†; Medazine; Nauzine; Norizine†; Triazine; Valoid; Singapore: used to treat the serotonin syndrome (p.416) in patients who have Marzine†; Swed.: Marzine†; Switz.: Marzine; UK: Valoid; USA: Bonine for Kids; Marezine. developed the syndrome after overdoses involving serotonergic Pharmacokinetics drugs or who have had their antidepressant therapy changed Multi-ingredient: Austria: Echnatol B ; Migril; Fin.: Vertipam; Hong After absorption from the gastrointestinal tract, cypro- without an adequate wash-out period.1,2 Kong: Migril†; Wellconal†; Irl.: Cyclimorph; Diconal†; Migril†; Neth.: Ercy- cof†; S.Afr.: Cyclimorph; Migril; Wellconal; UK: Cyclimorph; Diconal; Migril. heptadine hydrochloride undergoes almost complete 1. Lappin RI, Auchincloss EL. Treatment of the serotonin syn- metabolism. Metabolites are excreted principally in the drome with cyproheptadine. N Engl J Med 1994; 331: 1021–2. 2. McDaniel WW. Serotonin syndrome: early management with cy- urine as conjugates, and also in the faeces. proheptadine. Ann Pharmacother 2001; 35: 870–3. Sexual dysfunction. Cyproheptadine has been tried in the Cyproheptadine Hydrochloride Uses and Administration management of sexual dysfunction induced by SSRIs (see Ef- (BANM, rINNM) Cyproheptadine, a piperidine derivative, is a sedating fects on Sexual Function under Fluoxetine, p.393) but may pos- antihistamine with antimuscarinic, serotonin-antago- sibly reduce the effectiveness of the SSRI. Ciproheptadin-hidroklorid; Ciproheptadino hidrocloridas; Cy- proheptadine, chlorhydrate de; Cyproheptadin-hydrochlorid nist, and calcium-channel blocking actions. It is used as Preparations seskvihydrát; Cyproheptadinhydroklorid; Cyproheptadini hydro- the hydrochloride for the symptomatic relief of allergic BP 2008: Cyproheptadine Tablets; chloridum; Cyproheptadini Hydrochloridum Sesquihydricum; conditions including urticaria and angioedema (p.565), USP 31: Cyproheptadine Hydrochloride Syrup; Cyproheptadine Hydro- Hidrocloruro de ciproheptadina; Siproheptadin Hidroklorür; rhinitis (p.565) and conjunctivitis (p.564), and in pru- chloride Tablets. Syproheptadiinihydrokloridi. 4-(5H-Dibenzo[a,d]cyclohepten-5- ritic skin disorders (p.565). Other uses include the Proprietary Preparations (details are given in Part 3) Austral.: Periactin; Austria: Periactin; Belg.: Periactin; Braz.: Periatin; ylidene)-1-methylpiperidine hydrochloride sesquihydrate. management of migraine (p.564). Cyproheptadine hy- Preptin†; Chile: Viternum; Cz.: Peritol; Denm.: Periactin†; Fr.: Periactine; Ципрогептадина Гидрохлорид drochloride is given as the sesquihydrate although dos- Ger.: Peritol; Hong Kong: Cyprogin; Hung.: Peritol; India: Apenorm†; Ciplactin; Peritol; Practin; Indon.: Alphahist; Apeton; Cydifar; Cylat; En- es are expressed in terms of the anhydrous substance. C21H21N,HCl,1 ⁄ H2O = 350.9. namax; Esprocy; Glocyp; Heptasan; Lexahist; Poncohist; Profut; Prohessen; Anhydrous cyproheptadine hydrochloride 10 mg is Pronicy; Sinapdin; Irl.: Periactin; Ital.: Periactin; Mex.: Viternum; Neth.: CAS — 129-03-3 (cyproheptadine); 969-33-5 (anhydrous Periactin; NZ: Periactin; Pol.: Peritol; Port.: Trimetabol†; Viternum; Rus.: cyproheptadine hydrochloride); 41354-29-4 (cyprohepta- equivalent to about 11 mg of cyproheptadine hydro- Peritol (Перитол); S.Afr.: Cipla-Actin; Periactin; Singapore: Cyprotin; chloride sesquihydrate. Spain: Klarivitina†; Periactin; Viternum; Swed.: Periactin; Switz.: Periactin†; dine hydrochloride sesquihydrate). Thai.: Cyheptine; Cyprogin; Cyprono; Cyprosian; Cyprotec; Hepdine; Peri- ATC — R06AX02. For allergic conditions and pruritus the oral dose in actin; Polytab; Turk.: Prakten; Sipraktin; UK: Periactin; Venez.: Cyprodin; Eptacor†; Periactin†. ATC Vet — QR06AX02. adults is initially 4 mg three times daily, adjusted as Multi-ingredient: Arg.: Apeplus; Apetitol Forte; Ciprocort; Ciprovit Cal- necessary. The average dose requirement is 12 to cio; Ciprovit Energizante; Ciprovit Magnesico; Mikesan; Nipiol†; Potencil; 16 mg daily in three or four divided doses, but up to Sudevil Vita; Braz.: Apetivit BC; Apetiviton BC; Apevitin BC; Apmed; Bona- petit†; Cobactin; Cobaglobal; Cobavit; Cobavital; Polivitam†; Trimetabol; 32 mg daily may occasionally be necessary. The dose Chile: Apetrol; Grisetin Con Carnitina†; Orodina; Peracon; Revil; Rodepan; for children aged 2 to 6 years is 2 mg two or three times Viternum Vitaminado; Hong Kong: Petina Compound; Tres Orix Forte; Ital.: Carpantin†; Mex.: Cipro-Dexol†; Ciprolisina; Pangavit Pediatrico; Ro- daily increasing to a maximum of 12 mg daily and for cavit; Spain: Anti Anorex Triple; Childrevit†; Covitasa B12; Desarrol; children aged 7 to 14 years, 4 mg two or three times Enoton; Glotone; Medenorex; Pantobamin; Pranzo; Stolina; Tonico Juven- tus; Tres Orix Forte†; Trimetabol; Troforex Pepsico; Vita Menal; Venez.: daily up to a maximum of 16 mg daily. Cyprohepta- Cipromet†; Cyprodex. dine is not recommended in debilitated elderly pa- tients. N A dose of 4 mg is used for both prophylaxis and treat- Deptropine Citrate (BANM, rINNM) CH ment of migraine and other vascular headaches and Citrato de deptropina; Deptropiinisitraatti; Deptropincitrat; 3 may be repeated after 30 minutes; patients who re- Deptropin-citrát; Deptropine, citrate de; Deptropini citras; Dep- (cyproheptadine) spond usually obtain relief with 8 mg, and this dose tropino citratas; Dibenzheptropine Citrate. (1R,3r,5S)-3-(10,11- should not be exceeded within a 4- to 6-hour period. A Dihydro-5H-dibenzo[a,d]cyclohepten-5-yloxy)tropane dihydro- maintenance dose of 4 mg may be given every 4 to 6 gen citrate. Pharmacopoeias. In Chin., Eur. (see p.vii), Jpn, and US. Дептропина Цитрат Ph. Eur. 6.2 (Cyproheptadine Hydrochloride). A white or slight- hours. C H NO,C H O = 525.6. ly yellow, crystalline powder. Slightly soluble in water; sparingly Other cyproheptadine salts that have been given orally 23 27 6 8 7 soluble in alcohol; freely soluble in methyl alcohol. Protect from CAS — 604-51-3 (deptropine); 2169-75-7 (deptropine ci- include the acetylaspartate, aspartate, cyclamate, oro- trate). light. USP 31 (Cyproheptadine Hydrochloride). A white to slightly tate, acefyllinate (7-theophyllineacetate), and the pyri- ATC — R06AX16. yellow, odourless or practically odourless, crystalline powder. doxal phosphate salt (dihexazine). ATC Vet — QR06AX16. Soluble 1 in 275 of water, 1 in 35 of alcohol, 1 in 26 of chloro- form, and 1 in 1.5 of methyl alcohol; practically insoluble in Abdominal migraine. Cyproheptadine has been tried in the prophylactic treatment of children with abdominal migraine (see ether. H3C Pizotifen, p.624). N Adverse Effects and Precautions Angina pectoris. Cyproheptadine was used successfully to treat 2 patients with Prinzmetal’s angina (p.1157) refractory to As for the sedating antihistamines in general, p.561. In- standard treatment with calcium-channel blockers and nitrates.1 creased appetite and weight gain may occur with cy- Serotonin is an important endocrine mediator of coronary vasos- H proheptadine. pasm and the beneficial effects of cyproheptadine were attributed to its activity as a serotonin antagonist. O Abuse. Dependence developed in a patient who took about 1 1. Schecter AD, et al. Refractory Prinzmetal angina treated with 180 mg of cyproheptadine daily by mouth for 5 years. cyproheptadine. Ann Intern Med 1994; 121: 113–14. 1. Craven JL, Rodin GM. Cyproheptadine dependence associated with an atypical somatoform disorder. Can J Psychiatry 1987; Appetite disorders. Cyproheptadine has been widely used as 32: 143–5. an appetite stimulant, including for anorexia nervosa and cachex- ia (see under Megestrol, p.2115), but in the long-term appears to Effects on the nervous system. Antimuscarinic toxicity
Load more

Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Potential Drug Interactions and Potentially Inappropriate Medications in Daily Radiooncology Practice : a Risk Assessment
    From the Department of Radiotherapy and Radiation Oncology of Marienhospital Herne – University Hospital – of the Ruhr-Universität Bochum Director: Prof. Dr. med. I. A. Adamietz Potential drug interactions and potentially inappropriate medications in daily radiooncology practice – a risk assessment Inaugural-Dissertation for the Attainment of a Doctor´s Degree in Medicine at the high Medical Faculty of the Ruhr-Universität Bochum Presented by Nina Sibylle Lamberty from Düsseldorf 2013 Dean of Faculty: Prof. Dr. med Klaus Überla Referee: Prof. Dr. med. Irenäus A. Adamietz Co-Referee: PD Dr. med Oliver Lindner Date of oral exam: 03.02.2015 Abstract Lamberty Nina Potential drug interactions and potentially inappropriate medications in daily radiooncology practice – a risk assess- ment Background: Radiation treatment of malignant disease includes patients with various extents of tumor and different comorbidities. Due to bad general condition approximately 20 % of irradiated subjects are in-patients. Beyond elimi- nation of tumor and treatment of its side effects drug interactions and potentially inappropriate medications constitute a major challenge in these radiooncologic patients. The layering of polypharmacy with age and radiation related physiological and functional changes and comorbidities might increase the risk for potential drug drug interactions (pDDs). This study attempted to quantify the frequency of pDDIs and potential inappropriate medications (PIMs) not related to i.v. chemotherapy in patients undergoing radiation treatment aiming the assessment of risk by medication. Methods: Medication profiles were analyzed by reviewing discharge letters of 120 cancer patients who had been admitted to the Marienhospital, Herne between November 2010 and November 2011. An improvement of the Karnofsky index during hospital treatment had been registered.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0081713 A1 Sharma Et Al
    US 20100081713A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0081713 A1 Sharma et al. (43) Pub. Date: Apr. 1, 2010 (54) COMPOSITIONS AND METHODS FOR (22) Filed: Mar. 18, 2009 TREATINGVIRAL INFECTIONS Related U.S. Application Data (75) Inventors: Geeta Sharma, Singapore (SG); (60) Provisional application No. 61/069,917, filed on Mar. Ralf Altmeyer, Singapore (SG); 19, 2008. Vishal Pendharker, Singapore (SG); Yu Chen, Singapore (SG); Publication Classification Michael Foley, Chestnut Hill, MA (51) Int. Cl. (US) A63L/35 (2006.01) A6II 3L/25 (2006.01) Correspondence Address: A63L/35 (2006.01) Gearhart Law LLC A6II 3/13 (2006.01) 4 Femdale Avenue A6IP3L/2 (2006.01) Chatham, NJ 07928 (US) (52) U.S. Cl. .......... 514/459; 514/529; 514/647: 514/662 (73) Assignee: CombinatoRx, (Singapore) Pte. (57) ABSTRACT Ltd. The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infec (21) Appl. No.: 12/406,716 tion caused by an influenza virus). Patent Application Publication Apr. 1, 2010 Sheet 1 of 2 US 2010/0081713 A1 ------ 80 r -0. Vehicle 0.5% HPMC g - - Sertraline-30mg/kg/day - £ 60 “A Sertraline-100mg/kg/day/kg/day i -v. Oseltamivir-30mg/kg/day ...i -0. Oseltamivir-100mg/kg/day -0. (Sertraline 30mg/kg+ . 40 Prednisolone 0.1 mg/Kg) Figure 1 Patent Application Publication Apr. 1, 2010 Sheet 2 of 2 US 2010/0081713 A1 100 468OOO 2 O Wehicle Sentraline 10 mg/kg Sentraline 30mg/kg Setraline 100mg/kg Figure 2 US 2010/008 1713 A1 Apr.
    [Show full text]
  • Medicines Classification Committee
    Medicines Classification Committee Meeting date 1 May 2017 58th Meeting Title Reclassification of Sedating Antihistamines Medsafe Pharmacovigilance Submitted by Paper type For decision Team Proposal for The Medicines Adverse Reactions Committee (MARC) recommended that the reclassification to committee consider reclassifying sedating antihistamines to prescription prescription medicines when used in children under 6 years of age for the treatment of medicine for some nausea and vomiting and travel sickness [exact wording to be determined by indications the committee]. Reason for The purpose of this document is to provide the committee with an overview submission of the information provided to the MARC about safety concerns associated with sedating antihistamines and reasons for recommendations. Associated March 2013 Children and Sedating Antihistamines Prescriber Update articles February 2010 Cough and cold medicines clarification – antihistamines Medsafe website Safety information: Use of cough and cold medicines in children – new advice Medicines for Alimemazine Diphenhydramine consideration Brompheniramine Doxylamine Chlorpheniramine Meclozine Cyclizine Promethazine Dexchlorpheniramine New Zealand Some oral sedating antihistamines available without exposure to a prescription (pharmacist-only and pharmacy only), sedating therefore usage data is not easily available. antihistamines Table of Contents 1.0 PURPOSE ......................................................................................................................................
    [Show full text]
  • Proposed Changes to the 2021 FEI Equine Prohibited Substances List (EPSL) (Effective from 01.01.2022)
    Proposed changes to the 2021 FEI Equine Prohibited Substances List (EPSL) (effective from 01.01.2022) SUBSTANCE NAME CURRENT PROPOSED COMMENT STATUS EPSL CATEGORY ACETYLCHOLINESTERASE INHIBITOR Used in the treatment of Edrophonium Controlled Banned myasthenia gravis and Medication Substance has no legitimate use in the treatment of sports horses Used to increase Huperzine A Unlisted Banned alertness and treat Substance myasthenia gravis. The substance has no legitimate use in the treatment of sports horses. AMIDES Palmitoylethanolamid Banned Controlled Used in the treatment of Substance Medication joint pain ANGIOTENSIN CONVERTING ENZYME INHIBITORS Enalapril Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse Enalaprilat Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse Lisinopril Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse Moexipril Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse 1 Perindoprilat Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse ANTIHISTAMINES Antazoline Controlled Banned The substance has no Medication Substance legitimate use in the sports horse Azatadine Controlled Banned The substance has Medication Substance sedative effects
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]